A large group of top commercial law firms are advising on the spin-off of GSK and Pfizer’s consumer healthcare business, Haleon.
Pfiizer announced its decision to exit the joint venture and to sell its 32% stake following the announcement that Haleon is due to be listed on the stock market next month in a process likely to value it at around £40 billion.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
